52,035 Shares in Evolus, Inc. (NASDAQ:EOLS) Bought by Raymond James Financial Inc.

Raymond James Financial Inc. purchased a new position in Evolus, Inc. (NASDAQ:EOLS - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 52,035 shares of the company's stock, valued at approximately $575,000. Raymond James Financial Inc. owned approximately 0.08% of Evolus as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC raised its holdings in shares of Evolus by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 1,214,590 shares of the company's stock worth $13,412,000 after purchasing an additional 3,969 shares during the period. Schroder Investment Management Group lifted its holdings in Evolus by 2.5% in the fourth quarter. Schroder Investment Management Group now owns 1,040,440 shares of the company's stock worth $11,330,000 after acquiring an additional 25,480 shares during the last quarter. Rice Hall James & Associates LLC boosted its stake in Evolus by 4.8% in the fourth quarter. Rice Hall James & Associates LLC now owns 948,281 shares of the company's stock valued at $10,469,000 after acquiring an additional 43,381 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Evolus by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 421,481 shares of the company's stock valued at $4,653,000 after acquiring an additional 2,905 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in shares of Evolus by 63.5% during the third quarter. JPMorgan Chase & Co. now owns 169,926 shares of the company's stock valued at $2,753,000 after purchasing an additional 65,972 shares during the last quarter. 90.69% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on EOLS. Barclays raised their price target on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 price target on shares of Evolus in a report on Thursday. HC Wainwright restated a "buy" rating and issued a $27.00 price target on shares of Evolus in a research report on Thursday, April 10th. Finally, BTIG Research began coverage on shares of Evolus in a research report on Thursday, April 17th. They set a "buy" rating and a $21.00 price objective on the stock. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Evolus currently has an average rating of "Buy" and a consensus target price of $23.75.

Evolus Stock Down 2.9 %

EOLS traded down $0.29 during trading on Friday, hitting $9.80. The company had a trading volume of 1,361,358 shares, compared to its average volume of 672,080. The firm's 50-day moving average price is $11.66 and its 200 day moving average price is $12.56. The company has a market capitalization of $631.82 million, a PE ratio of -10.77 and a beta of 1.11. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. Evolus, Inc. has a one year low of $8.67 and a one year high of $17.82.

Insider Activity

In other Evolus news, CFO Sandra Beaver sold 8,996 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $119,286.96. Following the transaction, the chief financial officer now directly owns 173,583 shares in the company, valued at approximately $2,301,710.58. This represents a 4.93 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of Evolus stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $60,147.36. Following the transaction, the chief marketing officer now owns 95,671 shares of the company's stock, valued at $1,268,597.46. This represents a 4.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 60,575 shares of company stock valued at $794,369 over the last ninety days. 5.90% of the stock is currently owned by company insiders.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.